CA2054850A1 - Derives immino-cycliques, compositions pharmaceutiques qui contiennent de ces composes et procedes d'obtention - Google Patents

Derives immino-cycliques, compositions pharmaceutiques qui contiennent de ces composes et procedes d'obtention

Info

Publication number
CA2054850A1
CA2054850A1 CA2054850A CA2054850A CA2054850A1 CA 2054850 A1 CA2054850 A1 CA 2054850A1 CA 2054850 A CA2054850 A CA 2054850A CA 2054850 A CA2054850 A CA 2054850A CA 2054850 A1 CA2054850 A1 CA 2054850A1
Authority
CA
Canada
Prior art keywords
preparing
compounds
processes
pharmaceutical compositions
compositions containing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2054850A
Other languages
English (en)
Other versions
CA2054850C (fr
Inventor
Frank Himmelsbach
Volkhard Austel
Helmut Pieper
Wolfgang Eisert
Thomas Muller
Johannes Weisenberger
Gunter Linz
Gerd Kruger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2054850A1 publication Critical patent/CA2054850A1/fr
Application granted granted Critical
Publication of CA2054850C publication Critical patent/CA2054850C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2732-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572Five-membered rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
CA002054850A 1990-11-02 1991-11-01 Derives immino-cycliques, compositions pharmaceutiques qui contiennent de ces composes et procedes d'obtention Expired - Lifetime CA2054850C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4035961A DE4035961A1 (de) 1990-11-02 1990-11-02 Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DEP4035961.1 1990-11-02

Publications (2)

Publication Number Publication Date
CA2054850A1 true CA2054850A1 (fr) 1992-05-03
CA2054850C CA2054850C (fr) 2001-01-02

Family

ID=6418111

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002054850A Expired - Lifetime CA2054850C (fr) 1990-11-02 1991-11-01 Derives immino-cycliques, compositions pharmaceutiques qui contiennent de ces composes et procedes d'obtention

Country Status (25)

Country Link
US (2) US5541343A (fr)
EP (1) EP0483667B1 (fr)
JP (1) JP2937589B2 (fr)
KR (1) KR100223135B1 (fr)
AT (1) ATE163008T1 (fr)
BG (1) BG62025B2 (fr)
BR (1) BR1100445A (fr)
CA (1) CA2054850C (fr)
DE (2) DE4035961A1 (fr)
DK (1) DK0483667T3 (fr)
EE (1) EE03099B1 (fr)
ES (1) ES2113867T3 (fr)
FI (1) FI107606B (fr)
GR (1) GR3026508T3 (fr)
HK (1) HK1008742A1 (fr)
HU (2) HUT67288A (fr)
IE (1) IE913822A1 (fr)
IL (1) IL99926A (fr)
MX (1) MX9203677A (fr)
NO (1) NO174806B (fr)
NZ (1) NZ240463A (fr)
PT (1) PT99402B (fr)
RU (1) RU2040519C1 (fr)
SG (1) SG81852A1 (fr)
ZA (1) ZA918734B (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998006694A1 (fr) * 1996-08-16 1998-02-19 Du Pont Pharmaceuticals Company Amidinophenyl-pyrrolidines, -pyrrolines et -isoxazolidines et leurs derives
US5942544A (en) * 1996-02-22 1999-08-24 Dupont Pharmaceuticals Company α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors
US6057342A (en) * 1996-08-16 2000-05-02 Dupont Pharmaceutical Co. Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4127404A1 (de) * 1991-08-19 1993-02-25 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU646966B2 (en) * 1991-08-23 1994-03-10 Takeda Chemical Industries Ltd. 2-piperazinone compounds, their production and use
DE4213919A1 (de) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K Cyclische iminoderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DK0567967T3 (da) * 1992-04-28 1996-11-18 Thomae Gmbh Dr K Tritium-mærkede fibrinogen-receptor-antagonister, deres anvendelse og fremgangsmåde til deres fremstilling
DE4213931A1 (de) * 1992-04-28 1993-11-04 Thomae Gmbh Dr K Cyclische iminoderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4219158A1 (de) * 1992-06-11 1993-12-16 Thomae Gmbh Dr K Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4241632A1 (de) * 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5314902A (en) * 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
WO1994022820A1 (fr) * 1993-03-31 1994-10-13 G.D. Searle & Co. Amidinophenyl-1-pyrrolidones piperidinones azetinones inhibitrices de l'agregation plaquettaire
DE4424975A1 (de) * 1994-07-15 1996-01-18 Thomae Gmbh Dr K 2-Piperidinone, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0799202A1 (fr) * 1994-12-23 1997-10-08 Dr. Karl Thomae GmbH Derives de piperazine, medicaments contenant ces composes, leur utilisation et leur procede de preparation
CA2216162A1 (fr) * 1995-04-26 1996-10-31 Takeda Chemical Industries, Ltd. Piperazinones utiles comme inhibiteurs d'agregation plaquettaire
DE19515500A1 (de) * 1995-04-27 1996-10-31 Thomae Gmbh Dr K Substituierte Phenylamidine, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
US5719296A (en) * 1995-10-30 1998-02-17 Merck & Co., Inc. Pseudopeptide lactam inhibitors of peptide binding to MHC class II proteins
DE19604191A1 (de) * 1996-02-06 1997-08-07 Hoechst Schering Agrevo Gmbh 2,4-Diamino-1,3,5-triazine, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Pflanzenwachstumsregulatoren
DE19621483A1 (de) * 1996-05-29 1997-12-04 Hoechst Ag Substituierte 2-Naphthoylguanidine, Verfahren zur ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19621482A1 (de) 1996-05-29 1997-12-04 Hoechst Ag Substituierte 1-Naphthoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU8875798A (en) * 1997-08-29 1999-03-22 Proteus Molecular Design Ltd Meta-benzamidine derivatives as serin protease inhibitors
US6740682B2 (en) 1997-08-29 2004-05-25 Tularik Limited Meta-benzamidine derivatives as serine protease inhibitors
US5962504A (en) * 1997-09-08 1999-10-05 Georgetown University Substituted 2-pyrrolidinone activators of PKC
KR20010032175A (ko) 1997-11-20 2001-04-16 야스이 쇼사꾸 비페닐아미딘 유도체
WO1999050249A2 (fr) 1998-04-01 1999-10-07 Du Pont Pharmaceuticals Company Antagonistes de l'integrine
WO1999052861A1 (fr) * 1998-04-09 1999-10-21 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin NOUVEAUX DERIVES DE BENZYLGUANIDINE POUR LA THERAPIE ET LE DIAGNOSTIC IN VIVO ET $i(IN VITRO)
US6562828B1 (en) 1998-04-10 2003-05-13 Japan Tobacco Inc. Amidine compounds
SK15092000A3 (sk) * 1998-04-23 2001-05-10 Abbott Laboratories Pyrolidíny ako inhibítory neuraminidáz
US6518305B1 (en) 1998-04-23 2003-02-11 Abbott Laboratories Five-membered carbocyclic and heterocyclic inhibitors of neuraminidases
US6455571B1 (en) 1998-04-23 2002-09-24 Abbott Laboratories Inhibitors of neuraminidases
WO2000005234A1 (fr) * 1998-07-22 2000-02-03 Suntory Limited INHIBITEURS DE NF-λB CONTENANT DES DERIVES D'INDANE EN TANT QU'INGREDIENT ACTIF
US6284796B1 (en) * 1998-08-06 2001-09-04 Abbott Laboratories Ukokinase inhibitors
DE19844787A1 (de) * 1998-09-30 2000-04-13 Boehringer Ingelheim Pharma Disubstituierte Pyrrolidinone, diese Verbindung enthaltende Arzneimittel und deren Verwendung sowie ihre Herstellung
US6362201B1 (en) 1999-03-02 2002-03-26 Merck & Co., Inc. 3-cyclopropyl and 3-cyclobutyl pyrrolidine modulators of chemokine receptor activity
CA2360740A1 (fr) 1999-03-02 2000-09-08 Boehringer Ingelheim Pharmaceuticals, Inc. Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s
US6489354B1 (en) 1999-03-02 2002-12-03 Merck & Co., Inc. 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity
US6372764B1 (en) 1999-03-02 2002-04-16 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
US6420364B1 (en) 1999-09-13 2002-07-16 Boehringer Ingelheim Pharmaceuticals, Inc. Compound useful as reversible inhibitors of cysteine proteases
FR2817257B1 (fr) * 2000-11-30 2009-03-20 Sanofi Synthelabo Cyclohexyl(alkyl)-propanolamines, leur preparation et compositions pharmaceutiques en contenant
WO2002060894A2 (fr) 2001-01-30 2002-08-08 Bristol-Myers Squibb Company Lactames sulfonamide inhibiteurs de facteur xa
DE10121003A1 (de) * 2001-04-28 2002-12-19 Aventis Pharma Gmbh Anthranilsäureamide, Verfahren zur Herstellung, ihrer Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
GB0114005D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
GB0114004D0 (en) 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
JP4399253B2 (ja) * 2001-06-20 2010-01-13 ワイス プラスミノゲンアクチベーターインヒビター−1(pai−1)のインヒビターとしての、置換されたインドール酸誘導体
TWI224101B (en) * 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
JP2006514640A (ja) * 2002-12-10 2006-05-11 ワイス プラスミノゲンアクティベータインヒビターのインヒビターとしての置換3−アルキル及び3−アリールアルキル1h−イル酢酸誘導体
WO2004052855A2 (fr) * 2002-12-10 2004-06-24 Wyeth Derives substitues d'acides 3-carbonyl-1h-indol-1-yl acetique comme inhibiteurs de l'ihibiteur-1 d'activation plasminogenique
UA80453C2 (en) * 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
DK1569901T3 (da) * 2002-12-10 2009-02-16 Wyeth Corp Aryl-, aryloxy- og alkoxysubstituerede 1H-indol-3-yl-glyoxylsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1)
JP2006516593A (ja) * 2003-02-07 2006-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Mmp−9依存性疾患の治療及び予防のためのジピリダモール又はモピダモールの使用
WO2004093881A2 (fr) 2003-04-24 2004-11-04 Boehringer Ingelheim International Gmbh Utilisation du dipyridamole ou du mopidamole pour le traitement et la prevention de maladies thrombo-emboliques et de troubles induits par la formation excessive de thrombine et/ou par l'expression elevee des recepteurs de la thrombine
MXPA05012323A (es) * 2003-05-16 2006-01-30 Merck Sharp & Dohme Sulfonamidas ciclicas para la inhibicion de gama-secretasa.
US7163954B2 (en) * 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7332521B2 (en) * 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7141592B2 (en) * 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7446201B2 (en) * 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
US7265148B2 (en) * 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7442805B2 (en) * 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7420083B2 (en) * 2003-09-25 2008-09-02 Wyeth Substituted aryloximes
US7268159B2 (en) * 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7351726B2 (en) * 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7534894B2 (en) 2003-09-25 2009-05-19 Wyeth Biphenyloxy-acids
US7342039B2 (en) * 2003-09-25 2008-03-11 Wyeth Substituted indole oximes
US7411083B2 (en) * 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
EP1677783A2 (fr) 2003-10-08 2006-07-12 Nicholas Piramal India Limited Antagonistes du recepteur du fibrinogene et leur utilisation
BRPI0507374A (pt) * 2004-02-02 2007-07-10 Pfizer Prod Inc moduladores do receptor de histamina-3
CN101001836B (zh) 2004-05-07 2010-12-22 詹森药业有限公司 作为11-β羟基类固醇脱氢酶抑制剂的吡咯烷-2-酮和哌啶-2-酮衍生物
WO2006023865A1 (fr) * 2004-08-23 2006-03-02 Wyeth Acides d'oxazolo-naphthyl utilises en tant modulateurs de l'inhibiteur de type-1 (pai-1) de l'activateur de plasminogene utiles dans le traitement de la thrombose et des maladies cardio-vasculaires
RU2007106869A (ru) 2004-08-23 2008-09-27 Вайет (Us) Тиазол-нафтиловые кислоты как ингибиторы ингибитора активации плазминогена-1
US7186749B2 (en) * 2004-08-23 2007-03-06 Wyeth Pyrrolo-naphthyl acids and methods for using them
WO2006024627A2 (fr) * 2004-08-30 2006-03-09 Janssen Pharmaceutica N.V. Derives d'acetamides n-2 adamantanyl-2-phenoxy utilises en tant qu'inhibiteurs de la deshydrogenase 11-beta hydroxysteroide
DE602005017159D1 (de) 2004-08-30 2009-11-26 Janssen Pharmaceutica Nv Oxysteroid-dehydrogenase-inhibitoren
CN101039908B (zh) * 2004-08-30 2010-06-23 詹森药业有限公司 作为11-β羟甾类脱氢酶抑制剂的三环内酰胺衍生物
WO2006114096A1 (fr) * 2005-04-25 2006-11-02 Danmarks Tekniske Universitet Analogues de la dipeptide pyrrolidinone et leur utilisation en tant qu'edulcorants artificiels
JP2009504762A (ja) * 2005-08-17 2009-02-05 ワイス 置換インドール類およびそれらの使用方法
RU2014151622A (ru) 2007-10-05 2015-08-20 Акусела Инк. Композиции и способы лечения нейродегенеративных заболеваний
AU2008317107B2 (en) * 2007-10-23 2013-09-12 Allergan, Inc. Therapeutic substituted lactams
ES2897527T3 (es) 2009-07-02 2022-03-01 Acucela Inc Farmacología de moduladores del ciclo visual
US20130267699A1 (en) 2011-06-24 2013-10-10 California Institute Of Technology Quaternary heteroatom containing compounds
US8822679B2 (en) * 2011-06-24 2014-09-02 California Institute Of Technology Quaternary heteroatom containing compounds
US9518034B2 (en) 2013-10-14 2016-12-13 California Institute Of Technology Synthesis of chiral enaminones, their derivatives, and bioactivity studies thereof
AU2014352830B2 (en) 2013-11-21 2018-12-13 Concordia University, Inc. Substituted (4'-hydroxyphenyl)cycloalkane compounds and uses thereof as selective agonists of the estrogen receptor beta isoform
US10421696B2 (en) 2014-12-18 2019-09-24 California Institute Of Technology Enantioselective synthesis of α-quaternary mannich adducts by palladium-catalyzed allylic alkylation
CA2981041C (fr) 2015-03-27 2023-09-05 California Institute Of Technology Alkylation decarboxylative catalytique asymetrique d'alkyle au moyen de faibles concentrations de catalyseur et d'un precatalyseur robuste
EP3426391A4 (fr) 2016-03-11 2019-08-28 California Institute of Technology Compositions et procédés d'acylation de lactames
EP3480190B1 (fr) 2017-11-01 2023-01-04 California Institute of Technology Procédés d'alkylation allylique énantiosélective d'esters, lactones et lactames avec des alcools allyliques inactivés
US11214568B2 (en) 2018-10-18 2022-01-04 California Institute Of Technology Gem-disubstituted pyrrolidines, piperazines, and diazepanes, and compositions and methods of making the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4247466A (en) * 1979-07-05 1981-01-27 American Cyanamid Company Lactone metabolites of 3-(4-biphenylylcarbonyl)propionic acid
EP0194548A3 (fr) * 1985-03-12 1988-08-17 Dr. Karl Thomae GmbH Composés sulfonylaminoéthyl, médicament contenant ces composés et leur procédé de préparation
EP0196184B1 (fr) * 1985-03-16 1992-09-16 The Wellcome Foundation Limited Dérivés arylés
DE3823299A1 (de) * 1988-07-07 1990-01-11 Schering Ag Substituierte phenyl-pyrrolidin-2-one, -oxazolidin-2-one und -imidazolidin-2-one, ihre herstellung sowie verwendung in arzneimitteln

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
US6248772B1 (en) 1993-04-28 2001-06-19 Sumitomo Pharmaceuticals Co., Ltd. Indoloylguanidine derivatives
US5942544A (en) * 1996-02-22 1999-08-24 Dupont Pharmaceuticals Company α-branched anilines, toluenes, and analogs thereof as factor Xa inhibitors
WO1998006694A1 (fr) * 1996-08-16 1998-02-19 Du Pont Pharmaceuticals Company Amidinophenyl-pyrrolidines, -pyrrolines et -isoxazolidines et leurs derives
US6057342A (en) * 1996-08-16 2000-05-02 Dupont Pharmaceutical Co. Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof

Also Published As

Publication number Publication date
FI915136A0 (fi) 1991-10-31
JPH04264068A (ja) 1992-09-18
RU2040519C1 (ru) 1995-07-25
NO174806B (no) 1994-04-05
EP0483667A2 (fr) 1992-05-06
US5541343A (en) 1996-07-30
PT99402A (pt) 1992-09-30
DE4035961A1 (de) 1992-05-07
DK0483667T3 (da) 1998-09-23
HK1008742A1 (en) 1999-05-14
SG81852A1 (en) 2001-07-24
NO914294D0 (no) 1991-11-01
JP2937589B2 (ja) 1999-08-23
AU8692691A (en) 1992-05-07
EP0483667A3 (en) 1992-09-16
KR920009793A (ko) 1992-06-25
EE03099B1 (et) 1998-06-15
DE59108930D1 (de) 1998-03-12
HU913455D0 (en) 1992-01-28
KR100223135B1 (ko) 1999-10-15
FI915136A (fi) 1992-05-03
FI107606B (fi) 2001-09-14
IL99926A0 (en) 1992-08-18
NZ240463A (en) 1997-04-24
GR3026508T3 (en) 1998-07-31
IE913822A1 (en) 1992-05-22
MX9203677A (es) 1992-07-01
AU650488B2 (en) 1994-06-23
PT99402B (pt) 1999-04-30
BG62025B2 (bg) 1998-12-30
IL99926A (en) 1996-06-18
US5591769A (en) 1997-01-07
HU211563A9 (en) 1995-12-28
EP0483667B1 (fr) 1998-02-04
CA2054850C (fr) 2001-01-02
NO174806C (fr) 1994-07-13
HUT67288A (en) 1995-03-28
ZA918734B (en) 1993-05-04
NO914294L (no) 1992-05-04
ES2113867T3 (es) 1998-05-16
BR1100445A (pt) 2000-07-18
ATE163008T1 (de) 1998-02-15

Similar Documents

Publication Publication Date Title
CA2054850A1 (fr) Derives immino-cycliques, compositions pharmaceutiques qui contiennent de ces composes et procedes d'obtention
EP0528369A3 (fr) Dérivés à fonction imine cyclique, compositions pharmaceutiques les contenant et procédé pour leur préparation
CA2238859A1 (fr) Derives d'acides amines, compositions pharmaceutiques contenant ces composes et procedes de preparation de ceux-ci
IL105517A0 (en) Cyclic imino derivatives,their preparation and pharmaceutical compositions containing them
NO923466L (no) Heterocykliske forbindelser med 5 ledd, fremgangsmaate forfremstilling, samt legemidler som inneholder disse forbindelser
NO922940L (no) Fem-leddete heterocykliske forbindelser, fremgangsmaate for deres fremstilling og legemidler inneholdende dem
CA2049514A1 (fr) Derives de 3-amidopyrazole, procede d'obtention et compositions pharmaceutiques qui en contiennent
HUT59400A (en) Process for producing thiazole acylamino derivatives substituted with heterocyclic group, as well as pharmaceutical compositions comprising such compounds as active ingredient
CA2159450A1 (fr) 1-amidinophenyl-pyrrolidones piperidinones azetinones, inhibiteurs de l'agregation plaquettaire
HUT61780A (en) Process for producing new peptides and pharmaceutical compositions comprising same as active ingredient
NO940524L (fr)
CA2140927A1 (fr) Inhibiteurs d'agregation plaquettaire
CA2112083A1 (fr) Composes aryliques heterocycliques substitues
TH14549A (th) อนุพันธ์ของแอมิดีนชนิดใหม่ การเตรียมและประโยชน์ของอนุพันธ์เหล่านี้
TH14549EX (th) อนุพันธ์ของแอมิดีนชนิดใหม่ การเตรียมและประโยชน์ของอนุพันธ์เหล่านี้
RU93058275A (ru) Производные тиофен-2-карбоновой кислоты, способ их получения, фармацевтическая композиция и способ ее получения

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry